Skip to main content

JAK2 mutations in Asian patients with essential thrombocythaemia

Buy Article:

$51.00 plus tax (Refund Policy)

Background/Aim: JAK2V617F is an acquired mutation present in a considerable proportion of patients with chronic myeloproliferative disorders. Its reported prevalence in European and US studies of patients with essential thrombocythaemia (ET) is 23–57%. This study was conducted to determine the prevalence of the JAK2 mutation in Asian ET patients, and to examine their disease profile.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: JAK2 mutations; bleeding; cytoreductive therapy; essential thrombocythaemia; thrombosis

Document Type: Research Article

Affiliations: 1: Department of Haematology, Singapore General Hospital and 2: Molecular Diagnosis Centre, Department of Laboratory Medicine, National University Hospital, Singapore

Publication date: 2011-02-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more